Skip to main content

Caris Adds 14 New Markers to Breast Cancer PGx Test

Premium

Caris Life Sciences said this week that it is adding 14 new biomarkers to its Caris Target Now breast cancer pharmacogenetic test, which the company hopes will help physicians make treatment decisions for patients with early-stage disease.

"Previously, the biomarkers analyzed had been most useful for breast cancer patients with refractory or metastatic disease, as well as those patients who had exhausted treatment options within the standard of care — a group representing 15 percent of all breast cancer patients," the company said in a statement. "The recent biomarker additions expand the potential clinical utility to include women who face therapeutic ambiguity earlier in the disease continuum — a group representing nearly 50 percent of all breast cancer patients."

Caris listed TLE3, TOP2A, and Ki67 as a few of the new markers added to the Target Now panel associated with therapeutic response for commonly administered breast cancer chemotherapies.

According to the company, Target Now has been used to guide therapy for more than 10,000 patients with breast and other types of cancer since 2008.

Earlier this year, Caris announced the launch of a biomarker-driven real-time data repository that doctors can use to help them gauge how patients will respond to certain chemotherapies, immunotherapies, and biological therapies. The registry collects information about patients using Caris' Target Now suite of molecular profiling services, including the genetic profile of patients' tumors, their cancer treatment history, and their clinical outcome (PGx Reporter 02/17/10).

"Our Caris Target Now Evidence Team continues to accumulate and aggregate evidence to enhance the clinical utility of this tumor profiling tool," Les Paul, senior VP for Medical Affairs at Caris Life Sciences, said in a statement. "The ongoing process ensures that only the most relevant and appropriate information is included in the Caris Target Now panel. Better information can lead to better decisions, and better decisions can lead to better outcomes for patients."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.